PD-1 Non-Small Cell Lung Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharma

The PD-1 Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“PD-1 Non-Small Cell Lung Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 Non-Small Cell Lung Cancer Market.

Some of the key takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel PD-1 Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. 
• PD-1 Non-Small Cell Lung Cancer companies working in the treatment market are Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corp, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Pfizer, AstraZeneca, Seagen, and others, are developing therapies for the PD-1 Non-Small Cell Lung Cancer treatment 

• Emerging PD-1 Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others are expected to have a significant impact on the PD-1 Non-Small Cell Lung Cancer market in the coming years.   
• In June 2023, Qilu Pharmaceutical showcased a Trials in Progress poster presentation at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023), focusing on QL1706 (iparomlimab/tuvonralimab). QL1706 is an innovative bifunctional antibody designed for immunotherapy, featuring in two Phase III clinical studies for non-small cell lung carcinoma (NSCLC).
• In May 2023, Summit Therapeutics declared the enrollment of the first patient in the United States for the Phase III HARMONi study. This study, termed HARMONi, is a multiregional Phase III trial that is randomized and double-blinded. It aims to assess the safety and effectiveness of ivonescimab alongside chemotherapy in patients diagnosed with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have experienced progression after undergoing treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) like osimertinib.
• In May 2023, Gilead Sciences and Arcus Biosciences shared updated findings from an interim analysis of the ARC-7 study involving patients diagnosed with first-line, metastatic non-small cell lung cancer (NSCLC). These patients had a PD-L1 tumor proportion score (TPS) of 50% and lacked epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. The progression-free survival curves exhibited an early and consistent divergence of both treatment arms containing domvanalimab from the zimberelimab arm. This separation suggests potential therapeutic advantages linked to inhibiting the TIGIT pathway.
• In October 2022, Akeso Biopharma revealed that the China National Medical Products Administration’s Center for Drug Evaluation (CDE) awarded Breakthrough Therapy Designation (BTD) for Ivonescimab (AK112), a PD-1/VEGF bispecific antibody. This designation applies to its combination with docetaxel in treating patients diagnosed with locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) who have not shown positive responses to previous PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.
• In October 2022, GSK reported encouraging initial findings from the PERLA phase II trial involving Jemperli (dostarlimab) combined with chemotherapy for patients with metastatic non-squamous non-small cell lung cancer. The safety and tolerance of dostarlimab in this trial aligned with outcomes seen in prior clinical studies using comparable treatments. The most frequently observed treatment-related adverse effects included anemia, asthenia, nausea, constipation, cough, dyspnea, vomiting, reduced appetite, and neutropenia.

PD-1 Non-Small Cell Lung Cancer Overview

Due to its dismal prognosis, lung cancer continues to be the primary cause of cancer-related mortality globally. Immunocheckpoint blocking that targets programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has drastically altered the therapy landscape for patients with non-small-cell lung cancer (NSCLC), which is encouraging.

Get a Free Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight

Emerging PD-1 Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• GB226: Genor Biopharma
• BA-1104: Shandong Boan Biotechnology
• PF-06801591: Pfizer
• AZD2936: AstraZeneca
• HX008: Lepu Biopharma
• Dostarlimab: GlaxoSmithKline
• INCMGA00012: Incyte Corporation
• AK-112: Akeso Biopharma
• Zimberelimab: Arcus Biosciences
• Ivonescimab: Summit Therapeutics
• Sasanlimab: Pfizer
• Rilvegostomig: AstraZeneca
• SGN-PDL1V: Seagen

PD-1 Non-Small Cell Lung Cancer Route of Administration

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

PD-1 Non-Small Cell Lung Cancer Molecule Type

PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

• Monoclonal antibody
• Small molecule
• Peptide

PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

• PD-1 Non-Small Cell Lung Cancer Assessment by Product Type
• PD-1 Non-Small Cell Lung Cancer By Stage and Product Type
• PD-1 Non-Small Cell Lung Cancer Assessment by Route of Administration
• PD-1 Non-Small Cell Lung Cancer By Stage and Route of Administration
• PD-1 Non-Small Cell Lung Cancer Assessment by Molecule Type
• PD-1 Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight’s PD-1 Non-Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further PD-1 Non-Small Cell Lung Cancer product details are provided in the report. Download the PD-1 Non-Small Cell Lung Cancer pipeline report to learn more about the emerging PD-1 Non-Small Cell Lung Cancer therapies

Some of the key companies in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for PD-1 Non-Small Cell Lung Cancer are – Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New Age Pharmaceutical, Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Symphogen, and others.

PD-1 Non-Small Cell Lung Cancer Pipeline Analysis:

The PD-1 Non-Small Cell Lung Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer Treatment.
• PD-1 Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PD-1 Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer drugs and therapies

PD-1 Non-Small Cell Lung Cancer Pipeline Market Drivers

• Increase in Patient Burden, development of Efficient Novel Treatments, increasing healthcare expenditures are some of the important factors that are fueling the PD-1 Non-Small Cell Lung Cancer Market.

PD-1 Non-Small Cell Lung Cancer Pipeline Market Barriers

• However, uncertainty about the clinical response to PD-1/PD-L1 blockade therapy in NSCLC, NSCLC with driver mutations represent a challenging population and other factors are creating obstacles in the PD-1 Non-Small Cell Lung Cancer Market growth.

Scope of PD-1 Non-Small Cell Lung Cancer Pipeline Drug Insight    

• Coverage: Global
• Key PD-1 Non-Small Cell Lung Cancer Companies: Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corp, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Pfizer, AstraZeneca, Seagen, and others
• Key PD-1 Non-Small Cell Lung Cancer Therapies: GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others
• PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: PD-1 Non-Small Cell Lung Cancer current marketed and PD-1 Non-Small Cell Lung Cancer emerging therapies
• PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer market drivers and PD-1 Non-Small Cell Lung Cancer market barriers 

Request for Sample PDF Report for PD-1 Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials

Table of Contents

1. PD-1 Non-Small Cell Lung Cancer Report Introduction

2. PD-1 Non-Small Cell Lung Cancer Executive Summary

3. PD-1 Non-Small Cell Lung Cancer Overview

4. PD-1 Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics

6. PD-1 Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. PD-1 Non-Small Cell Lung Cancer Mid Stage Products (Phase II)

8. PD-1 Non-Small Cell Lung Cancer Early Stage Products (Phase I)

9. PD-1 Non-Small Cell Lung Cancer Preclinical Stage Products

10. PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment

11. PD-1 Non-Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. PD-1 Non-Small Cell Lung Cancer Key Companies

14. PD-1 Non-Small Cell Lung Cancer Key Products

15. PD-1 Non-Small Cell Lung Cancer Unmet Needs

16 . PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers

17. PD-1 Non-Small Cell Lung Cancer Future Perspectives and Conclusion

18. PD-1 Non-Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services